Document is current
Any future updates will be listed below
-
Authors
Frazier, Thomas W. https://orcid.org/0000-0002-6951-2667
Jaini, Ritika https://orcid.org/0000-0002-4580-8789
Busch, Robyn M. https://orcid.org/0000-0002-5442-4912
Wolf, Matthew
Sadler, Tammy
Klaas, Patricia
Hardan, Antonio Y. https://orcid.org/0000-0002-9860-8625
Martinez-Agosto, Julian A. https://orcid.org/0000-0001-6776-6949
Sahin, Mustafa https://orcid.org/0000-0001-7044-2953
Eng, Charis https://orcid.org/0000-0002-3693-5145
,
Warfield, Simon K.
Scherrer, Benoit
Dies, Kira
Filip-Dhima, Rajna
Gulsrud, Amanda
Hanson, Ellen
Phillips, Jennifer M.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02461446 at ClinicalTrials.govDocuments that mention this clinical trial
Cross-level analysis of molecular and neurobehavioral function in a prospective series of patients with germline heterozygous PTEN mutations with and without autism
https://doi.org/10.1186/s13229-020-00406-6
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U54NS092090)
Ambrose Monell Foundation
Autism Speaks
Hartwell Foundation
- License Information
-
More Information
Article History
Received: 2 October 2020
Accepted: 15 December 2020
First Online: 28 January 2021
Ethics approval and consent to participate
: The study was approved by the local institutional review boards of the participating centers, and written informed consent was obtained from all participants or their legal guardians with assent obtained from participants age < 18 years who were deemed able to provide assent.
: Not applicable.
: TWF has received funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from Quadrant Biosciences, Impel NeuroPharma, F. Hoffmann-La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, Roche Pharma, National Institutes of Health, and the Brain and Behavior Research Foundation and has an investor stake in Autism EYES LLC. JAMA has no competing interests. MS reports grant support from Novartis, Roche, Pfizer, Ipsen, LAM Therapeutics, Astellas, Aucta, Bridgebio, and Quadrant Biosciences. He has served on Scientific Advisory Boards for Sage, Roche, Celgene, Aeovian, Regenxbio, and Takeda.
